WASHINGTON (AP) — The Food and Drug Administration has approved Genentech’s Avastin for a new use against late-stage cervical cancer, the seventh indication for the blockbuster biotech drug.

The FDA approved the drug late Thursday for women with cervical cancer that is persistent, recurrent or has spread to other parts of the body. The disease is usually caused by the human papillomavirus, which is spread through sexual contact and causes cells to become cancerous.